In recent years, the explosively emergence of novel biologic agents, including B-cell targeted monoclonal immunoglobulin, FcRn inhibitors, and complement inhibitors changed the treatment strategy for MG and provided more faster, more effective, and less adverse effects choices for patients with MG (20, 27, 28). This evidence concerns the gene FCGRT and myasthenia gravis.